BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Davin JC, van de Kar NC. Advances and challenges in the management of complement-mediated thrombotic microangiopathies. Ther Adv Hematol 2015;6:171-85. [PMID: 26288712 DOI: 10.1177/2040620715577613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Shi K, Wang Z, Liu Y, Gong Y, Fu Y, Li S, Wood K, Hao J, Zhang G, Shi F, Yan Y. CFHR1-Modified Neural Stem Cells Ameliorated Brain Injury in a Mouse Model of Neuromyelitis Optica Spectrum Disorders. J I 2016;197:3471-80. [DOI: 10.4049/jimmunol.1600135] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
2 Choo SZ, Brown F. Subclinical atypical haemolytic uremic syndrome relapse following discontinuation of eculizumab: aHUS relapse post eculizumab cessation. Nephrology 2017;22:4-6. [DOI: 10.1111/nep.12931] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Kallianpur AR, Bradford Y, Mody RK, Garman KN, Comstock N, Lathrop SL, Lyons C, Saupe A, Wymore K, Canter JA, Olson LM, Palmer A, Jones TF. Genetic Susceptibility to Postdiarrheal Hemolytic-Uremic Syndrome After Shiga Toxin-Producing Escherichia coli Infection: A Centers for Disease Control and Prevention FoodNet Study. J Infect Dis 2018;217:1000-10. [PMID: 29216383 DOI: 10.1093/infdis/jix633] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Winters JL. Plasma exchange in thrombotic microangiopathies (TMAs) other than thrombotic thrombocytopenic purpura (TTP). Hematology Am Soc Hematol Educ Program 2017;2017:632-8. [PMID: 29222314 DOI: 10.1182/asheducation-2017.1.632] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
5 Raufi AG, Scott S, Darwish O, Harley K, Kahlon K, Desai S, Lu Y, Tran MH. Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab. Hematol Rep 2016;8:6625. [PMID: 27781079 DOI: 10.4081/hr.2016.6625] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
6 Torres EA, Chang Y, Desai S, Chang I, Zuckerman JE, Burwick R, Kalantar-Zadeh K, Hanna RM. Complement-Mediated Thrombotic Microangiopathy Associated with Lupus Nephritis Treated with Eculizumab: A Case Report. Case Rep Nephrol Dial 2021;11:95-102. [PMID: 33977097 DOI: 10.1159/000512227] [Reference Citation Analysis]
7 Zhang K, Lu Y, Harley KT, Tran MH. Atypical Hemolytic Uremic Syndrome: A Brief Review. Hematol Rep 2017;9:7053. [PMID: 28626544 DOI: 10.4081/hr.2017.7053] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
8 Macia M, de Alvaro Moreno F, Dutt T, Fehrman I, Hadaya K, Gasteyger C, Heyne N. Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome. Clin Kidney J. 2017;10:310-319. [PMID: 28621343 DOI: 10.1093/ckj/sfw115] [Cited by in Crossref: 8] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
9 Mehmood T, Taylor M, Winters JL. Management of Thrombotic Microangiopathic Hemolytic Anemias with Therapeutic Plasma Exchange: When It Works and When It Does Not. Hematol Oncol Clin North Am 2016;30:679-94. [PMID: 27113004 DOI: 10.1016/j.hoc.2016.01.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
10 Yousaf F, Spinowitz B, Charytan C, Galler M. Pernicious Anemia Associated Cobalamin Deficiency and Thrombotic Microangiopathy: Case Report and Review of the Literature. Case Rep Med 2017;2017:9410727. [PMID: 28265287 DOI: 10.1155/2017/9410727] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
11 Ranganathan D, John GT. Therapeutic Plasma Exchange in Renal Disorders. Indian J Nephrol 2019;29:151-9. [PMID: 31142960 DOI: 10.4103/ijn.IJN_420_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]